Cited by 197Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

Open access

van Harten, Argonde C., Visser, Pieter Jelle, Pijnenburg, Yolande A.L., Teunissen, Charlotte E., Blankenstein, Marinus A., Scheltens, Philip, van der Flier, Wiesje M.·2013·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2012.08.004

Open this paper in CoChat — free account

Abstract

Background: The need to recognize Alzheimer's disease (AD) as early as possible led us to evaluate the predictive value of amyloid β(1‐42) (Aβ42), total tau (tau), and phosphorylated tau (ptau) in cerebrospinal fluid (CSF) for clinical progression in patients with subjective complaints. Methods: We recruited nondemented patients with subjective complaints (i.e., criteria for mild cognitive impairment [MCI] not fulfilled) from our memory clinic. We assessed the predictive value of CSF Aβ42, tau, and ptau for clinical progression using Cox proportional hazards models adjusted for age, gender, and baseline findings on the Mini‐Mental State Examination (MMSE). Clinical progression was defined as progression to MCI or AD. Results: We included 127 patients with subjective complaints (age 60 ± 10 years, 61 [48%] females, MMSE 29 ± 1). At baseline, Aβ42 and tau were abnormal in 20 patients (both 16%), and ptau in 32 patients (25%). Thirteen patients (10%) progressed to MCI (n = 11) or AD (n = 2). Aβ42 was the strongest predictor of progression to MCI or AD with an adjusted hazard ratio (HR) of 16.0 (3.8–66.4). The adjusted HR associated with tau was 2.8 (0.9–9.2) and with ptau 2.6 (0.8–8.2). Combinations of biomarkers had a lower predictive value than Aβ42 alone. Conclusion: Low Aβ42 was the strongest predictor of clinical progression in patients with subjective complaints. These results are in line with the hypothesis that the cascade of pathologic events starts with deposition of Aβ42, whereas neuronal degeneration and hyperphosphorylation of tau are more downstream events, closer to clinical manifestation of AD.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.08.004

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Self-citation
Telephone Interview for Cognitive Status
Brandt, J., Spencer, M., & Folstein, M. F. (1988) · PsycTESTS Dataset · doi:10.1037/t28542-000 · Cited by 1,504
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059

Show all 43 references

Sorted by citations

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citation
Alzheimer’s Disease
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citation
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014
Self-citation
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Alzheimer's disease
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Self-citation
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citation
Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis
Mitchell, A. J., Beaumont, H., Ferguson, D. Y., Yadegarfar, M., & Stubbs, B. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12336 · Cited by 1,228
Subjective Cognitive Decline in Preclinical Alzheimer's Disease
Rabin, L. A., Smart, C. M., & Amariglio, R. E. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045136 · Cited by 590
Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies
Rabin, L. A., Initiative, T. A. D. N., Smart, C. M., Crane, P. K., Amariglio, R. E., Berman, L., Boada, M., Buckley, R. F., Chételat, G., Dubois, B., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150154 · Cited by 496
Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia
Slot, R. E. R., Sikkes, S. A. M., Berkhof, J., Brodaty, H., Buckley, R., Cavedo, E., Dardiotis, E., Guillo‐Benarous, F., Hampel, H., Kochan, N. A., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.003 · Cited by 428
Self-citation
Amsterdam Dementia Cohort: Performing Research to Optimize Care
van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170850 · Cited by 395
Self-citation
Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease
Liguori, C., Romigi, A., Nuccetelli, M., Zannino, S., Sancesario, G., Martorana, A., Albanese, M., Mercuri, N. B., Izzi, F., Bernardini, S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2510 · Cited by 365
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
Verberk, I. M. W., Slot, R. E., Verfaillie, S. C. J., Heijst, H., Prins, N. D., van Berckel, B. N. M., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2018) · Annals of Neurology · doi:10.1002/ana.25334 · Cited by 315
Self-citation
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Self-citation
From Subjective Cognitive Complaints to Dementia
Mendonça, M., Alves, L., & Bugalho, P. (2015) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515592331 · Cited by 278
Functional cognitive disorders: a systematic review
McWhirter, L., Ritchie, C., Stone, J., & Carson, A. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30405-5 · Cited by 240
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)
Jessen, F., Spottke, A. E., Boecker, H., Brosseron, F., Büerger, K., Catak, C., Fließbach, K., Franke, C., Fuentes, M., Heneka, M. T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0314-2 · Cited by 229
Subjective Cognitive Concerns and Neuropsychiatric Predictors of Progression to the Early Clinical Stages of Alzheimer Disease
Donovan, N. J., Amariglio, R. E., Zoller, A. S., Rudel, R. K., Gómez‐Isla, T., Blacker, D., Hyman, B. T., Locascio, J. J., Johnson, K. A., Sperling, R. A., et al. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2014.02.007 · Cited by 234
Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer’s Disease Biomarkers Changes
Liguori, C., Mercuri, N. B., Izzi, F., Romigi, A., Cordella, A., Sancesario, G., & Placidi, F. (2017) · SLEEP · doi:10.1093/sleep/zsx011 · Cited by 221
Fluid biomarkers in Alzheimer’s disease – current concepts
Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 221
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
Ritchie, C. W., Smailagic, N., Noel-Storr, A. H., Ukoumunne, O. C., Ladds, E. C., & Martin, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010803.pub2 · Cited by 217
Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease
Jessen, F. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0539-z · Cited by 214
Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis
Parnetti, L., Chipi, E., Salvadori, N., D’Andrea, K., & Eusebi, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0459-7 · Cited by 206
ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
Ebenau, J. L., Timmers, T., Wesselman, L. M. P., Verberk, I. M. W., Verfaillie, S. C. J., Slot, R. E. R., van Harten, A. C., Teunissen, C. E., Barkhof, F., van den Bosch, K. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009724 · Cited by 191
Self-citation
Self-reported memory complaints
Kryscio, R. J., Abner, E. L., Cooper, G. E., Fardo, D. W., Jicha, G. A., Nelson, P. T., Smith, C. D., Eldik, L. J. V., Wan, L., & Schmitt, F. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000856 · Cited by 196
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
Hampel, H. J., (APMI), F. T. A. P. M. I., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179932 · Cited by 184
Gray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165
Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer’s Disease: Potential and Limitations
Cosín‐Tomás, M., Antonell, A., Lladó, A., Alcolea, D. A., Fortea, J., Ezquerra, M., Lleó, A., Martı́, M. J., Pallàs, M., Sánchez‐Valle, R., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0088-8 · Cited by 161
Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?
Studart‐Neto, A., & Nitríni, R. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1003002 · Cited by 167
EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects
Gouw, A. A., Alsema, A. M., Tijms, B. M., Borta, A., Scheltens, P., Stam, C. J., & van der Flier, W. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.017 · Cited by 149
Self-citation
Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort
de Wilde, A., van der Flier, W. M., Pelkmans, W., Bouwman, F. H., Verwer, J. H., Groot, C., van Buchem, M. M., Zwan, M. D., Ossenkoppele, R., Yaqub, M. M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1346 · Cited by 154
Self-citation
From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.
Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150
Preclinical AD predicts decline in memory and executive functions in subjective complaints
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a8418b · Cited by 143
Self-citation
Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease
Antonell, A., Mansilla, A., Rami, L., Lladó, A., Iranzo, Á., Olives, J., Balasa, M., Sánchez‐Valle, R., & Molinuevo, J. L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140624 · Cited by 141
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
Self-citation
Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results
Slot, R. E. R., Verfaillie, S. C. J., Overbeek, J. M., Timmers, T., Wesselman, L. M. P., Teunissen, C. E., Dols, A., Bouwman, F. H., Prins, N. D., Barkhof, F., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0390-y · Cited by 131
Self-citation
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study
van Maurik, I. S., Vos, S. J. B., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Barkhof, F., Frölich, L., Kornhuber, J., Wiltfang, J., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30283-2 · Cited by 131
Self-citation
Autophagy in health and disease: From molecular mechanisms to therapeutic target
Lu, G. X., Wang, Y., Shi, Y. P., Zhang, Z., Huang, C., He, W., Wang, C., & Shen, H. (2022) · MedComm · doi:10.1002/mco2.150 · Cited by 135
Mindfulness training for older adults with subjective cognitive decline: Results from a pilot randomized controlled trial.
Smart, C. M., Segalowitz, S. J., Mulligan, B. P., Koudys, J., & Gawryluk, J. R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150992 · Cited by 123
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 123
Self-citation
Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment
Wolfsgruber, S., Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161252 · Cited by 114
Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
Forlenza, O. V., Radanovic, M., Talib, L. L., Aprahamian, I., Diniz, B. S., Zetterberg, H., & Gattaz, W. F. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.003 · Cited by 114
Assessing brain plasticity across the lifespan with transcranial magnetic stimulation: why, how, and what is the ultimate goal?
Freitas, C., Farzan, F., & Pascual‐Leone, Á. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00042 · Cited by 117
Subjective Cognitive Decline and Related Cognitive Deficits
Si, T., Xing, G., & Han, Y. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00247 · Cited by 109
Memory self-awareness in the preclinical and prodromal stages of Alzheimer’s disease
Vannini, P., Amariglio, R. E., Hanseeuw, B. J., Johnson, K. A., McLaren, D. G., Chhatwal, J. P., Pascual‐Leone, Á., Rentz, D. M., & Sperling, R. A. (2017) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.04.002 · Cited by 108
Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment
Fernández-Blázquez, M. A., Ávila-Villanueva, M., Maestú, F., & Medina, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150956 · Cited by 98
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Self-citation
Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project
van Maurik, I. S., Zwan, M. D., Tijms, B. M., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Wattjes, M. P., Barkhof, F., Berkhof, J. H., van der Flier, W. M., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2712 · Cited by 91
Self-citation
Apolipoproteins E and J interfere with amyloid‐beta uptake by primary human astrocytes and microglia in vitro
Mulder, S. D., Nielsen, H. M., Blankenstein, M. A., Eikelenboom, P., & Veerhuis, R. (2014) · Glia · doi:10.1002/glia.22619 · Cited by 86
Self-citation
Exercise-Related Changes of Networks in Aging and Mild Cognitive Impairment Brain
Huang, P., Fang, R., Li, B., & Chen, S. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00047 · Cited by 89
Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course
Liguori, C., Placidi, F., Izzi, F., Spanetta, M., Mercuri, N. B., & Pucchio, A. D. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0571-3 · Cited by 77
CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
Papaliagkas, V. T., Kalinderi, K., Vareltzis, P. K., Μoraitou, D., Papamitsou, T., & Chatzidimitriou, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108976 · Cited by 79
Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives
Sun, Y., Yang, F., Lin, C., & Han, Y. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12395 · Cited by 71
Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline
Verfaillie, S. C. J., Tijms, B. M., Versteeg, A., Benedictus, M. R., Bouwman, F. H., Scheltens, P., Barkhof, F., Vrenken, H., & van der Flier, W. M. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.10.007 · Cited by 70
Self-citation
White matter degeneration in subjective cognitive decline: a diffusion tensor imaging study
Li, X.-Y., Tang, Z.-C., Sun, Y., Tian, J., Liu, Z.-Y., & Han, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10091 · Cited by 65
Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions
Ossenkoppele, R., van der Flier, W. M., Verfaillie, S. C. J., Vrenken, H., Versteeg, A., van Schijndel, R. A., Sikkes, S. A. M., Twisk, J. W. R., Adriaanse, S. M., Zwan, M. D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000432 · Cited by 63
Self-citation
Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
Verfaillie, S. C. J., Timmers, T., Slot, R. E. R., van der Weijden, C. W. J., Wesselman, L. M. P., Prins, N. D., Sikkes, S. A. M., Yaqub, M., Dols, A., Lammertsma, A. A., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00007 · Cited by 63
Self-citation
Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI
Wolfsgruber, S., Jessen, F., Koppara, A., Kleineidam, L., Schmidtke, K., Frölich, L., Kurz, A., Schulz, S., Hampel, H. J., Heuser, I., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001399 · Cited by 63
Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease
Rostamzadeh, A., Bohr, L., Wagner, M., Baethge, C., & Jessen, F. (2022) · Neurology · doi:10.1212/wnl.0000000000201072 · Cited by 61
Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study
Hessen, E., Eckerström, M., Nordlund, A., Almdahl, I. S., Stålhammar, J., Bjerke, M., Eckerström, C., Göthlin, M., Fladby, T., Reinvang, I., et al. (2017) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000454676 · Cited by 63
Gray matter network disruptions and amyloid beta in cognitively normal adults
Tijms, B. M., Kate, M. T., Wink, A. M., Visser, P. J., Ecay, M., Clerigue, M., Estanga, A., Garcia Sebastian, M., Izagirre, A., Villanua, J., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.015 · Cited by 59
Self-citation
Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice
Sauvée, M., Didierlaurent, G., Latarche, C., Escanyé, M., Olivier, J. L., & Malaplate, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131838 · Cited by 58
Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive Decline
Rodríguez‐Gómez, O., Ruiz, C. A., Jessen, F., Valero, S., & Boada, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150189 · Cited by 57
Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project
Verberk, I. M. W., Hendriksen, H. M. A., van Harten, A. C., Wesselman, L. M. P., Verfaillie, S. C. J., van den Bosch, K. A., Slot, R. E. R., Prins, N. D., Scheltens, P., Teunissen, C. E., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.007 · Cited by 56
Self-citation
Silymarin effect on amyloid-β plaque accumulation and gene expression of APP in an Alzheimer’s disease rat model
Yaghmaei, P., Azarfar, K., Dezfulian, M., & Ebrahim‐Habibi, A. (2014) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-22-24 · Cited by 55
A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline
Verfaillie, S. C. J., Slot, R. E. R., Dicks, E., Prins, N. D., Overbeek, J. M., Teunissen, C. E., Scheltens, P., Barkhof, F., van der Flier, W. M., & Tijms, B. M. (2018) · Human Brain Mapping · doi:10.1002/hbm.24065 · Cited by 50
Self-citation
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline
Lista, S., Molinuevo, J. L., Cavedo, E., Rami, L., Amouyel, P., Teipel, S. J., Garaci, F., Toschi, N., Habert, M.-O., Blennow, K., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150202 · Cited by 53
High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline
Verfaillie, S. C. J., Witteman, J., Slot, R. E. R., Pruis, I. J., Vermaat, L. E. W., Prins, N. D., Schiller, N. O., van de Wiel, M. A., Scheltens, P., van Berckel, B. N. M., et al. (2019) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2019.05.006 · Cited by 51
Self-citation
Subjective Cognitive Decline, Cognitive Reserve Indicators, and the Incidence of Dementia
Jia, F., Li, Y., Li, M., & Cao, F. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.08.005 · Cited by 54
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease
Buckley, R. F., Villemagne, V. L., Masters, C. L., Ellis, K. A., Rowe, C. C., Johnson, K. A., Sperling, R. A., & Amariglio, R. E. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0810-z · Cited by 51
The ATN Framework—Moving Preclinical Alzheimer Disease to Clinical Relevance
van der Flier, W. M., & Scheltens, P. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2967 · Cited by 50
Self-citation
Amyloid and Tau Biomarkers in Subjective Cognitive Impairment
Colijn, M. A., & Grossberg, G. T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150180 · Cited by 51
Subjective Cognitive Decline and APOE ɛ4: A Systematic Review
Ali, J. I., Smart, C. M., & Gawryluk, J. R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180248 · Cited by 48
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project
Initiative, F. T. A. D. N., van Maurik, I. S., Slot, R. E. R., Verfaillie, S. C. J., Zwan, M. D., Bouwman, F. H., Prins, N. D., Teunissen, C. E., Scheltens, P., Barkhof, F., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0487-y · Cited by 47
Self-citation
Soluble Amyloid-β Consumption in Alzheimer’s Disease
Espay, A. J., Sturchio, A., Schneider, L. S., & Ezzat, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210415 · Cited by 46
Reduced future‐oriented decision making in individuals with subjective cognitive decline: A functional MRI study
Hu, X., Uhle, F., Fließbach, K., Wagner, M., Han, Y., Weber, B., & Jessen, F. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.02.005 · Cited by 43
Five‐year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?
Tarnanas, I., Tsolaki, A., Wiederhold, M. D., Wiederhold, B. K., & Tsolaki, M. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.10.005 · Cited by 46
Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies
Hu, X., Teunissen, C. E., Spottke, A. E., Heneka, M. T., Düzel, E., Peters, O., Li, S., Priller, J., Büerger, K., Teipel, S. J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.002 · Cited by 43
Self-citation
Subjective Cognitive Decline and Alzheimer's Disease Spectrum Disorder
Hong, Y. J., & Lee, J. (2017) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2017.16.2.40 · Cited by 44
Accelerated long-term forgetting in healthy older adults predicts cognitive decline over 1 year
Wearn, A. R., Saunders-Jennings, E., Nurdal, V., Hadley, E., Knight, M. J., Newson, M., Kauppinen, R. A., & Coulthard, E. J. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00693-4 · Cited by 40
Comparison of odor identification among amnestic and non-amnestic mild cognitive impairment, subjective cognitive decline, and early Alzheimer’s dementia
Park, S. J., Lee, J., Lee, K., & Kim, J. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3261-1 · Cited by 41
Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1‐42 in Alzheimer's Disease Neuroimaging Initiative participants
Li, W., Risacher, S. L., Gao, S., Boehm, S. L., Elmendorf, J. S., Saykin, A. J., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.11.002 · Cited by 39
Jiao-tai-wan inhibits inflammation of the gut-brain-axis and attenuates cognitive impairment in insomnic rats
Su, H., Zhang, C., Zou, X. G., Lu, F., Zeng, Y., Guan, H., Ren, Y., Yuan, F., Xu, L., Zhang, M., et al. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112478 · Cited by 39
Lifestyle Factors Are Important Contributors to Subjective Memory Complaints among Patients without Objective Memory Impairment or Positive Neurochemical Biomarkers for Alzheimer’s Disease
Miley-Åkerstedt, A., Jelić, V., Marklund, K., Walles, H., Åkerstedt, T., Hagman, G., & Andersson, C. (2018) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000493749 · Cited by 35
Relationship of cognitive strategy use to prospective memory performance in a diverse sample of nondemented older adults with varying degrees of cognitive complaints and impairment
Aronov, A., Rabin, L. A., Fogel, J., Chi, S. Y., Kann, S. J., Abdelhak, N., & Zimmerman, M. E. (2014) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2014.984653 · Cited by 42
Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 45
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Caldwell, J., Cummings, J. L., Banks, S. J., Palmqvist, S., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0565-1 · Cited by 38
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study
Sannemann, L., Schild, A., Altenstein, S., Bartels, C., Brosseron, F., Büerger, K., Cosma, N. C., Fließbach, K., Freiesleben, S. D., Glanz, W., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00701-7 · Cited by 39
SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMES
Kryscio, R. J., Abner, E. L., Jicha, G. A., Nelson, P. T., Smith, C. D., Eldik, L. J. V., Lou, W., Fardo, D. W., Cooper, G. E., & Schmitt, F. A. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.74 · Cited by 34
Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
Mofrad, R. B., Schoonenboom, N. S. M., Tijms, B. M., Scheltens, P., Visser, P. J., van der Flier, W. M., & Teunissen, C. E. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.10.004 · Cited by 33
Self-citation
Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study
Bruun, M., Frederiksen, K. S., Rhodius‐Meester, H. F. M., Baroni, M., Gjerum, L., Koikkalainen, J. R., Urhemaa, T., Tolonen, A. J., van Gils, M., Rueckert, D., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0482-3 · Cited by 31
Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus
Akiba, C., Nakajima, M., Miyajima, M., Ogino, I., Motoi, Y., Kawamura, K., Adachi, S., Kondo, A., Sugano, H., Tokuda, T., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180059 · Cited by 30
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 29
Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
van Wijk, N., Slot, R. E. R., Duits, F. H., Strik, M., Biesheuvel, E., Sijben, J., Blankenstein, M. A., Bierau, J., van der Flier, W. M., Scheltens, P., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.04.005 · Cited by 29
Self-citation
In Situ Monitoring the Aggregation Dynamics of Amyloid-β Protein Aβ42 in Physiological Media via a Raman-Based Frequency Shift Method
Zhu, W., Wang, Y., Xie, D., Cheng, L., Wang, P., Zeng, Q., Li, M., & Zhao, Y. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00257 · Cited by 28
Biomarker-based signature of alzheimer's disease in pre-MCI individuals
Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27
Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease
Kuo, H., Yen, H., Huang, C., Hsu, W., Wei, H.-J., & Lin, C. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.971787 · Cited by 27
Cerebral Amyloid Angiopathy, Alzheimer’s Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets
Furr, J. W., Morales‐Scheihing, D., Manwani, B., Lee, J., & McCullough, L. D. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08568-0 · Cited by 29
Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer’s Disease and Correlation with Cerebral Hypoperfusion Pattern
Mazzon, G., Ajčević, M., Cattaruzza, T., Menichelli, A., Guerriero, M., Capitanio, S., Pesavento, V., Dore, F., Sorbi, S., Manganotti, P., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190506141733 · Cited by 26

Authors: van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M.
Affiliations: Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Maastricht University Medical Centre (NL)
Corresponding author: van Harten, Argonde C.
ORCID: van Harten, Argonde C.
Visser, Pieter Jelle
Pijnenburg, Yolande A.L.
Teunissen, Charlotte E.
Blankenstein, Marinus A.
Scheltens, Philip
van der Flier, Wiesje M.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2012-12-10
Volume: 9
Issue: 5
Pages: 481-487
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2012.08.004
OpenAlex: W2013751858
Cited by: 197
References: 43
Citations by year: 2026: 4 · 2025: 9 · 2024: 11 · 2023: 11 · 2022: 5 · 2021: 11 · 2020: 19 · 2019: 20 · 2018: 23 · 2017: 20 · 2016: 16 · 2015: 20 · 2014: 19 · 2013: 9
FWCI: 10.97
Type: journal article
Language: en
Open access: green
research.vu.nl
Licence: other-oa
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Research Publications (Maastricht University) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Alzheimer Nederland and Stichting VUmc Fonds
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords: Alzheimer's disease, amyloid-beta 42
MeSH terms: Alzheimer Disease, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Biomarkers, Proportional Hazards Models, Amyloid beta-Peptides, tau Proteins, Disease Progression, Early Diagnosis, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks